The HIV market continues to grow nicely in the US and EU thanks to increased testing, which has been facilitated by recent legislation (#msg-31419107).
Here are some data** on penetration and market share as provided by GILD on its 3Q08 CC:
US patients (all lines) 154K on Atripla (28% share) 192K on Truvada (35% share) 23K on Viread (4% share) === 369K on tenofovir in some form (67% share) 182K on non-tenofovir regimens (33% share) === 551K total patients, +8% year-over-year
US patients (first-line only) Atripla: 55% share Truvada: 30% share Viread: negligible share === Tenofovir in some form: 85% share
Patients in top-5 EU countries (all lines) *9K on Atripla (3% share) 112K on Truvada (42% share) 59K on Viread (23% share) === 180K on tenofovir in some form (68% share) 85K on non-tenofovir regimens (32% share) === 265K total patients, +7% YoY
Top-5 EU countries (first-line only) Tenofovir in some form: 55% share
*Not yet reimbursed in France. **As of the end of 2Q08.
<font size=3><font color=red> “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.